Butterfly Medical Secures $21M to Advance Minimally Invasive BPH Treatment

Deal Summary

Butterfly Medical announced the closing of its Series C round, raising $21 million from investors including the European Innovation Council, Junson Capital, MedVenture and New Rhein Healthcare Investors. The funding will support regulatory filings and commercialisation of its minimally invasive BPH device. The round exceeded the company's target and validates its therapeutic approach.